TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER).
Amino acids provide substrates for protein synthesis and energy metabolism; dextrose provides caloric support.
| Metabolism | Amino acids are metabolized via transamination, deamination, and urea cycle; dextrose undergoes glycolysis and oxidative phosphorylation. |
| Excretion | Renal: 100% of infused amino acids and dextrose are metabolized or excreted; no intact drug excretion. Biliary/fecal: negligible. |
| Half-life | Not applicable; components are endogenous substances with rapid metabolic turnover. Exogenous amino acids have half-lives of minutes to hours, dextrose ~1-2 hours. |
| Protein binding | Amino acids: minimal to moderate binding to albumin and globulins (variable). Dextrose: not protein bound. |
| Volume of Distribution | Amino acids: approximate Vd 0.3-0.4 L/kg (total body water). Dextrose: Vd ~0.2 L/kg (extracellular fluid). |
| Bioavailability | 100% via intravenous route; not administered by other routes. |
| Onset of Action | Immediate upon IV infusion; metabolic effects begin within minutes as amino acids and glucose enter circulation. |
| Duration of Action | Duration is dependent on infusion rate and metabolic demand; continuous infusion maintains steady state; effects cease shortly after infusion stops. |
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day administered at a rate not exceeding 5 mL/kg/hour, based on protein and electrolyte requirements.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in anuria or oliguria. In renal impairment, dose adjustment required based on GFR: GFR 10-30 mL/min: reduce frequency to every 12-24 hours; GFR <10 mL/min: avoid use or use with extreme caution, typically at reduced volume. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Contraindicated or use with extreme caution, typically at 25% of normal dose. |
| Pediatric use | Weight-based dosing: 2-3 g of amino acids per kg per day (corresponding to approximately 73-109 mL/kg/day of Travasol 2.75%). Adjust according to metabolic requirements and clinical response; maximum infusion rate 0.1 g amino acids/kg/hour. |
| Geriatric use | Use with caution due to decreased renal and hepatic function; start at lower end of dosing range and adjust based on fluid and electrolyte status, monitoring for signs of fluid overload. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infants. |
| Teratogenic Risk | No adequate studies in pregnant women. In animal studies, no teratogenic effects observed at clinical doses. Risk cannot be excluded. Use during pregnancy only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
Solutions are hypertonic; infusion into peripheral veins may cause thrombophlebitis. Central venous administration is preferred.
| Serious Effects |
["Hypersensitivity to any component","Severe hyperglycemia","Hepatic coma","Severe azotemia"]
| Precautions | ["Risk of hyperglycemia, electrolyte imbalances, catheter-related infections, and metabolic acidosis. Monitor serum glucose, electrolytes, and acid-base status."] |
Loading safety data…
| Monitor maternal electrolytes, fluid balance, glucose levels, and signs of infection. Fetal monitoring for growth and well-being if used long-term. |
| Fertility Effects | No known effects on fertility based on available data. |